XILIO THERAPEUTICS
Dead / Abandoned — Abandoned — no statement of use filed (as of 11 Jul 2022)
What this means for you
This application is over — abandoned 11 Jul 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88783255
- Mark type
- Stylized text
- Filed
- 03 Feb 2020
- Published for opposition
- 02 Jun 2020
- Abandoned
- 11 Jul 2022
- Attorney of record
- Valerie Brennan
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of cancer, all of the foregoing excluding pharmaceutical products for sleep disorders, central nervous disorders (other than cancers of the central nervous system), and neurological disorders (other than cancers of the neurological system)
Owner
- XILIO DEVELOPMENT, INC., Waltham, MA, US
- Akrevia Therapeutics, Inc., Cambridge, MA, US
- Akrevia Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 11 Jul 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 11 Jul 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 25 Nov 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Nov 2021 — SOU EXTENSION 2 GRANTED
- 23 Nov 2021 — SOU EXTENSION 2 FILED
- 23 Nov 2021 — SOU TEAS EXTENSION RECEIVED
- 20 Jul 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Jul 2021 — SOU EXTENSION 1 GRANTED
- 08 Jun 2021 — SOU EXTENSION 1 FILED
- 13 Jul 2021 — NOTICE OF REVIVAL - E-MAILED
- 13 Jul 2021 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 13 Jul 2021 — PETITION TO REVIVE-GRANTED
- 13 Jul 2021 — TEAS PETITION TO REVIVE RECEIVED
- 12 Jul 2021 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 12 Jul 2021 — ABANDONMENT - NO USE STATEMENT FILED